Provided by Tiger Trade Technology Pte. Ltd.

BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

374.47
+5.311.44%
Post-market: 374.470.00000.00%19:30 EDT
Volume:252.60K
Turnover:95.12M
Market Cap:42.69B
PE:67.00
High:379.48
Open:375.00
Low:374.37
Close:369.16
52wk High:385.22
52wk Low:253.95
Shares:114.00M
Float Shares:85.69M
Volume Ratio:0.59
T/O Rate:0.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.59
EPS(LYR):2.47
ROE:14.66%
ROA:7.46%
PB:8.25
PE(LYR):151.61

Loading ...

Leadership Reshuffle Sweeps Pharmaceutical Sector: Hengrui, Fosun, AstraZeneca, Pfizer Among Key Players

Deep News
·
May 07

BeOne Medicines Shares Surge After Robust First-Quarter

Dow Jones
·
May 07

BEIGENE's Q1 Net Profit Soars 399% Sequentially, Shares Jump 7% Post-Earnings

Deep News
·
May 07

BEIGENE Shares Surge Over 4% Post-Earnings on Stellar Q1 Performance

Stock News
·
May 07

Lithium Carbonate Spot Prices Surge Significantly; BEIGENE Reports 178-Fold Jump in Q1 Net Profit

Stock News
·
May 07

Stock Track | BeOne Medicines Soars 5.19% Intraday on Strong Q1 2026 Earnings and Positive Guidance

Stock Track
·
May 06

BEIGENE Reports Q1 2026 Net Profit of 1.608 Billion Yuan

Stock News
·
May 06

GUIDANCE: (ONC) BeOne Medicines Expects 2026 Revenue Range $6.3B - $6.5B, vs. FactSet Est of $6.4B

MT Newswires Live
·
May 06

Press Release: BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates

Dow Jones
·
May 06

Is It Too Late To Consider BeOne Medicines (ONC) After Its 23% One Year Gain?

Simply Wall St.
·
May 06

BeOne Medicines AG expected to post earnings of 87 cents a share - Earnings Preview

Reuters
·
May 04

BeOne Medicines Receives US FDA Priority Review for Tevimbra Combination Therapy

MT Newswires Live
·
Apr 29

Earning Preview: BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS this quarter’s revenue is expected to increase by 17.70%, and institutional views are bullish

Earnings Agent
·
Apr 29

BEIGENE Secures Global Exclusive Rights to Develop Trispecific Therapy Through Huahui Anjian Partnership

Stock News
·
Apr 27

Press Release: BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6

Dow Jones
·
Apr 22

Beigene Reports Profit Turnaround with 2025 Net Income of 1.461 Billion Yuan

Stock News
·
Apr 14

Analysts Conflicted on These Healthcare Names: Johnson & Johnson (JNJ), BeOne Medicines (ONC) and Helus Pharma (HELP)

TIPRANKS
·
Apr 13

BeOne Medicines (ONC) Receives a Buy from Truist Financial

TIPRANKS
·
Apr 10

OncoC4 announces first participant's dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer's disease

prnewswire
·
Apr 09

RBC Capital Keeps Their Buy Rating on BeOne Medicines (ONC)

TIPRANKS
·
Apr 09